Equashield has raised $300 million in funding, reaching an estimated valuation of $1.3 billion. The company, headquartered in Port Washington, New York, develops advanced closed-system transfer devices (CSTDs) to ensure safe handling of hazardous drugs in healthcare environments. Supported by Nordic Capital, Equashield continues to lead innovation in medical safety technology, protecting healthcare professionals and patients worldwide.
What Is Equashield and What Does It Do?
Equashield, founded by Marino Kriheli and Eric Shem Tov in 2009, is a New York City-based medical device company specializing in closed-system transfer devices (CSTDs) for handling hazardous drugs safely. The company develops innovative solutions such as EQUASHIELD Pro, an automated compounding robot that prepares individual hazardous drug doses with enhanced speed, precision, and safety, protecting healthcare workers from exposure to harmful substances.
Equashield employs 59 people and serves hospitals, pharmacies, and clinics across the United States and internationally. Its focus on safety, efficiency, and accuracy has positioned the company as a leader in drug handling and compounding automation, helping healthcare providers minimize errors while safeguarding staff.
How Much Funding Has Equashield Raised?
1. Series D Round
- Amount Raised: $300M
- Date: October 2022
- Lead Investors: Nordic Capital
- Motivation: To scale operations, enhance product development, and expand global reach in hazardous drug safety solutions.
Total Funding Raised: $300 Million
Current Valuation: $1.3 Billion (as of October 2022)
Latest Funding Date: October 2022
Key Investors
1. Nordic Capital
- Details: A private equity firm headquartered in Copenhagen, Denmark, focused on building sustainable and growth-driven companies.
- Investment Focus Areas: Healthcare, technology, and industrial sectors.
- Notable Investments: Autocirc, Sunrise Medical, One Inc, iLOQ.
Where Is Equashield’s Headquarters?
Equashield is headquartered in Port Washington, New York, United States, strategically located to serve healthcare institutions across the country while maintaining close access to its manufacturing and R&D operations.
What’s Next for Equashield?
Equashield is poised to expand its global footprint in the healthcare sector by continuing to innovate in drug safety and automation technologies. The company plans to enhance its automated compounding systems and broaden adoption across hospitals, pharmacies, and oncology centers.
With strong backing from Nordic Capital and a growing demand for safer drug handling solutions, Equashield is well-positioned to strengthen its leadership in the medical device industry while advancing workplace safety and operational efficiency.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like Equashield . Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.
